Clinical Side Effect Comparison: What Research Shows
Understanding Wegovy Side Effects Compared to Mounjaro for Weight Management
When evaluating Wegovy side effects compared to Mounjaro, the fundamental difference lies in their mechanisms of action. Wegovy (semaglutide) is a GLP-1 receptor agonist, whilst Mounjaro (tirzepatide) is a dual GIP and GLP-1 receptor agonist. This dual mechanism may influence the frequency and intensity of gastrointestinal side effects, though both medications share similar profiles including nausea, vomiting, diarrhoea, and constipation. Clinical trials suggest that the most common side effects for both treatments are gastrointestinal, typically occurring during dose escalation phases.
The severity of side effects often correlates with how quickly doses are increased, which is why both treatments follow structured escalation schedules. Wegovy's 20-week escalation from 0.25mg to 2.4mg maintenance dose is designed to improve tolerability, whilst Mounjaro follows a similar gradual approach. Both prescription-only medicines require clinical assessment and ongoing monitoring to ensure side effects are manageable whilst achieving weight management goals alongside a reduced-calorie diet and increased physical activity.
Pricing and Clinical Value When Comparing Side Effect Profiles
Understanding Wegovy side effects compared to Mounjaro becomes more relevant when considering treatment accessibility and long-term value. Wegovy starts at £79.99 for the 0.25mg starter dose (with code FIRST40 applied at checkout), progressing through £94.99 (0.5mg), £99.99 (1mg), £139.99 (1.7mg), to £209.99 for the 2.4mg maintenance dose. Our Getting Started bundles, such as the Intro Duo (0.25mg & 0.5mg) at £169.99, provide convenient dose progression whilst monitoring side effect tolerance. Returning customers benefit from code DOSE25, making continued treatment more accessible if initial side effects prove manageable.
The clinical value extends beyond pricing when considering side effect management strategies. Our Take-It-Slow bundles, including the Gentle Start Trio (0.25mg, 0.25mg, 0.5mg) at £269.99, allow extended time at lower doses if side effects require slower progression. This flexibility can be crucial when comparing how individuals tolerate Wegovy versus Mounjaro, as some patients may need longer adaptation periods. Both treatments are available through our GPhC-registered pharmacy (#9012878) with clinical oversight throughout your weight management journey.
Clinical Trial Evidence: STEP vs SURPASS Side Effect Data
The STEP trials for Wegovy and SURPASS trials for Mounjaro provide valuable insights when evaluating side effects. In STEP 1, Wilding et al., NEJM, 2021, reported that nausea occurred in approximately 44% of Wegovy patients versus 16% with placebo, whilst vomiting affected 25% versus 6% respectively. Most gastrointestinal side effects were mild to moderate and decreased over time as patients adapted to treatment.
Comparative analysis suggests both treatments have similar discontinuation rates due to side effects, though individual tolerance varies significantly. The structured dose escalation in both protocols aims to minimise these effects whilst maintaining therapeutic efficacy. Patients considering either treatment should understand that side effects typically improve with continued use and appropriate dose management.
How Wegovy's Mechanism Influences Side Effects
Wegovy works as a GLP-1 receptor agonist, mimicking the natural hormone that regulates blood sugar and gastric emptying. This mechanism directly affects digestive processes, which explains why gastrointestinal side effects are most common during initial treatment phases. The medication slows gastric emptying, promoting feelings of fullness but potentially causing nausea, especially if eating patterns aren't adjusted accordingly. Understanding this mechanism helps patients manage side effects by eating smaller, more frequent meals and avoiding high-fat foods that may exacerbate symptoms. The once-weekly injection schedule provides consistent medication levels, which many patients find helps maintain stable side effect patterns compared to daily medications.
Ordering Process and Clinical Support for Side Effect Management
Starting your Wegovy journey involves a comprehensive 3-minute online clinical assessment that evaluates your suitability whilst considering potential side effect risks. Our prescribers review your medical history within 3 working days (or 24 hours with express service) to ensure safe treatment initiation. Once approved, your medication arrives via next-day cold-chain delivery with detailed guidance on managing common side effects. The assessment process specifically addresses previous experiences with similar medications, allowing prescribers to anticipate and plan for potential side effect management. This clinical oversight continues throughout treatment, with ongoing support available for dose adjustments or side effect concerns.
Storage Advantages and Practical Considerations
When comparing Wegovy side effects to Mounjaro, practical factors like storage can influence treatment success and side effect management. Wegovy offers superior storage flexibility, remaining stable at room temperature for up to 6 weeks once removed from refrigeration, compared to Mounjaro's 21-day limit. This advantage becomes particularly relevant for patients experiencing side effects who might need treatment breaks or travel flexibility during dose adjustments. The FlexTouch pen system provides precise, easy dosing that helps maintain consistent medication levels, potentially reducing side effect variability. Proper storage ensures medication stability, which directly impacts efficacy and side effect profiles throughout your treatment journey.
Personalised Side Effect Management Strategies
Individual responses to Wegovy side effects compared to Mounjaro vary considerably, making personalised treatment approaches essential. Some patients tolerate Wegovy's GLP-1-only mechanism better, whilst others may find Mounjaro's dual action more suitable for their physiology. Factors including previous medication experiences, existing medical conditions, and lifestyle patterns all influence side effect likelihood and severity. Our clinical team works with patients to identify optimal starting doses, escalation timing, and supportive strategies tailored to individual needs.
The flexibility to switch between treatments if side effects prove problematic provides additional reassurance for patients beginning their weight management journey. Both Wegovy and Mounjaro are available from EverydayMeds, allowing your prescriber to help determine which option aligns best with your tolerance profile and treatment goals. This comparative approach ensures you receive the most suitable treatment whilst maintaining clinical oversight throughout your weight management programme.
Next Steps: Beginning Your Clinically-Supervised Journey
Understanding Wegovy side effects compared to Mounjaro represents just the first step in your prescription weight loss journey. Our streamlined process begins with clinical assessment, progresses through careful dose escalation with side effect monitoring, and continues with ongoing support throughout treatment. New customers can start with code FIRST40, whilst returning patients benefit from DOSE25 at checkout, making long-term treatment more accessible. The combination of clinical expertise, medication choice flexibility, and comprehensive support ensures optimal outcomes whilst managing any side effects effectively. Visit https://everydaymeds.co.uk/collections/wegovy to begin your clinically-assessed weight management programme today.
Reviewed by the EverydayMeds Clinical Team · GPhC #9012878 · Last updated February 2026
